Page last updated: 2024-09-04

docetaxel anhydrous and calpeptin

docetaxel anhydrous has been researched along with calpeptin in 1 studies

Compound Research Comparison

Studies
(docetaxel anhydrous)
Trials
(docetaxel anhydrous)
Recent Studies (post-2010)
(docetaxel anhydrous)
Studies
(calpeptin)
Trials
(calpeptin)
Recent Studies (post-2010) (calpeptin)
12,1103,2166,920289099

Protein Interaction Comparison

ProteinTaxonomydocetaxel anhydrous (IC50)calpeptin (IC50)
Calpain-9Homo sapiens (human)2.84
Calpain-1 catalytic subunitHomo sapiens (human)0.3472
Procathepsin LHomo sapiens (human)0.072
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus4.81
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 24.81
Cathepsin KHomo sapiens (human)0.0001

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ansa-Addo, EA; Inal, J; Jorfi, S; Kholia, S; Lange, S; Stratton, D; Valley, S1

Other Studies

1 other study(ies) available for docetaxel anhydrous and calpeptin

ArticleYear
Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.
    Scientific reports, 2015, Aug-25, Volume: 5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Calpain; Cell Line, Tumor; Cell Proliferation; Cell-Derived Microparticles; Dipeptides; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Treatment Outcome

2015
chemdatabank.com